---
title: "Evommune begins Phase IIb trial of EVO756 for migraine"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294503057.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-31T10:13:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294503057.md)
  - [en](https://longbridge.com/en/news/294503057.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294503057.md)
generator: "portal-rs"
---

# Evommune begins Phase IIb trial of EVO756 for migraine

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [EVMN.US](https://longbridge.com/en/quote/EVMN.US.md)

## Related News & Research

- [Firefox for iOS Gets Built-In Ad Blocker](https://longbridge.com/en/news/297656638.md)
- [FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first](https://longbridge.com/en/news/297336275.md)
- [SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race](https://longbridge.com/en/news/297220838.md)
- [How Is Home Depot’s Stock Performance Compared to Other Consumer Discretionary Stocks](https://longbridge.com/en/news/297407039.md)
- ["Oreogate" on Instagram went viral. But was it all a fake ad for an AI company?](https://longbridge.com/en/news/297357874.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**